每年合成最多十种样品化合物（选项第 1 年）-猫眼课题宝

每年合成最多十种样品化合物（选项第 1 年）

批准号：

10701635

负责人：

JAMES TALTON

金额：

$63.73万

依托单位：

ALCHEM LABORATORIES CORPORATION

依托单位国家：

美国

项目类别：

财政年份：

2021

资助国家：

美国

项目状态：

已结题

起止时间：

2021-09-20 至 2023-09-19

来源：

https://reporter.nih.gov/project-details/10701635

关键词：

Contractor Developmental Therapeutics Program Drug Utilization Human Indoles Pharmaceutical Preparations Sampling Therapeutic Agents cancer therapy clinical development drug synthesis

项目摘要

项目成果

JAMES TALTON的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

The Developmental Therapeutics Program/DCTD utilizes the Drug Acquisition Initiative (DAI) to independently acquire gram quantities of all known therapeutic agents that are under human clinical development for the treatment of cancer. As part of the DAI the Drug Synthesis and Chemistry Branch periodically engages its contractors to synthesize gram quantities of select compounds. The Synthesis Target 1 Project is directed at the synthesis of a minimum of 5 grams of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, designated as CB-5339 and NSC831868.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文